Adding Tumor Lysate-Loaded Autologous Dendritic Cell Vaccination to Standard of Care Associated with Clinically Improved Overall Survival in Patients With Newly Diagnosed and Recurrent Glioblastoma | Medicine in 2 Minutes
1. In this phase 3 non-randomized controlled trial, among 331 patients, patients with newly diagnosed glioblastoma (nGBM) receiving dendritic cell vaccination (DCVax-L) had a median overall survival of 19.3 months versus 16.5 months in outpatient control patients treated with standard of care. 2. Patients with recurrent glioblastoma (rGBM) had a median overall survival of 13.2 …
